Proximagen Neuroscience PLC
Records under this name other than patents Proximagen Neuroscience PLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Proximagen Neuroscience PLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,465,467 | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases Formerly held Term ended Term ended May 19, 2020 · USPTO record | Term ended | Term ended May 19, 2020 | USPTO record |
| US 8,030,316 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine Formerly held Lapsed on the fee record Ended Oct 4, 2019 · USPTO record | Lapsed on the fee record | Ended Oct 4, 2019 | USPTO record |
| US 7,129,354 | Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds Formerly held Lapsed on the fee record Ended Oct 31, 2018 · USPTO record | Lapsed on the fee record | Ended Oct 31, 2018 | USPTO record |
| US 7,820,677 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine Formerly held Lapsed on the fee record Ended Oct 26, 2018 · USPTO record | Lapsed on the fee record | Ended Oct 26, 2018 | USPTO record |
| US 7,812,017 | 4-substituted indole and indoline compounds Formerly held Lapsed on the fee record Ended Oct 12, 2018 · USPTO record | Lapsed on the fee record | Ended Oct 12, 2018 | USPTO record |
| US 8,835,439 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases Formerly held Lapsed on the fee record Ended Sep 16, 2018 · USPTO record | Lapsed on the fee record | Ended Sep 16, 2018 | USPTO record |
| US 7,071,180 | Certain Arylaliphatic and Heteroaryl-Aliphatic Piperazinyl Pyrazines and Their Use in the Treatment of Serotonin-Related Diseases Formerly held Lapsed on the fee record Ended Jul 4, 2018 · Low confidence | Lapsed on the fee record | Ended Jul 4, 2018 | Low confidence |
| US 7,534,794 | Certain Arylaliphatic and Heteroaryl-Aliphatic Piperazinyl Pyrazines and Their Use in the Treatment of Serotonin-Related Diseases Formerly held Lapsed on the fee record Ended May 19, 2017 · Medium confidence | Lapsed on the fee record | Ended May 19, 2017 | Medium confidence |
| US 8,410,113 | (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof Formerly held Lapsed on the fee record Ended Apr 2, 2017 · USPTO record | Lapsed on the fee record | Ended Apr 2, 2017 | USPTO record |
| US 6,756,377 | Compounds and their use Formerly held Lapsed on the fee record Ended Jun 29, 2016 · USPTO record | Lapsed on the fee record | Ended Jun 29, 2016 | USPTO record |